Rabies Diagnosis and Treatment
For any patient with possible rabies exposure, immediately initiate post-exposure prophylaxis (PEP) consisting of thorough wound cleansing, rabies immune globulin (RIG) infiltration into and around the wound, and a 4-dose vaccine series on days 0,3,7, and 14—do not wait for laboratory confirmation as rabies is nearly 100% fatal once symptoms develop.
Diagnostic Approach
Clinical Assessment
- History of animal exposure is the cornerstone of diagnosis—specifically document any bite or non-bite exposure (scratches, mucous membrane contact with saliva) from mammals, particularly dogs, bats, raccoons, skunks, and foxes 1
- Clinical diagnosis alone is unreliable because rabies presents in multiple forms (furious, paralytic, and atypical), and relying solely on symptoms leads to under-reporting 2
- Consider rabies in any patient with encephalopathy of unknown cause 2
Laboratory Confirmation
- Nucleic acid amplification (PCR) is the preferred diagnostic test due to excellent sensitivity and specificity, applicable to multiple specimen types including saliva, skin biopsies from the nape of the neck, and cerebrospinal fluid 2
- MRI patterns may help differentiate rabies from other viral encephalitides 2
- Critical caveat: Do not delay PEP while awaiting laboratory results—diagnosis is primarily for surveillance and confirmation, not for treatment decisions 3
Treatment Protocol
For Previously Unvaccinated Persons
Step 1: Immediate Wound Care
- Cleanse all wounds thoroughly with soap and water for 15 minutes 3
- If available, irrigate with a virucidal agent such as povidone-iodine solution 1
- This step is critical as it provides the first line of defense before virus enters neurons
Step 2: Rabies Immune Globulin (RIG)
- Administer 20 IU/kg body weight 1
- Infiltrate the full dose into and around all wounds if anatomically feasible—this is where the virus is located and must be neutralized 1
- Any remaining volume should be administered intramuscularly at a site distant from vaccine administration 1
- Never administer RIG in the same syringe as vaccine 1
- Do not exceed the recommended dose as RIG can partially suppress active antibody production 1
- Important pitfall: Only 56% of eligible patients receive proper wound infiltration in practice—ensure this critical step is not skipped 4
Step 3: Vaccine Administration
- Use human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV)
- Administer 1.0 mL intramuscularly on days 0,3,7, and 14 5, 1
- Deltoid area only for adults and older children; outer thigh for younger children 1
- Never use the gluteal area 1
- Day 0 is the day the first dose is administered—start immediately after exposure regardless of time interval 1
Special Population: Immunocompromised Patients
- Use a 5-dose regimen on days 0,3,7,14, and 28 1
For Previously Vaccinated Persons
Simplified Protocol:
- Perform thorough wound cleansing as above 1
- Do NOT administer RIG 1
- Administer vaccine 1.0 mL intramuscularly on days 0 and 3 only 1
- This applies to anyone with documented history of pre-exposure vaccination or prior PEP with cell-culture vaccines 1
Critical Timing Considerations
- Start PEP within 24 hours of exposure when possible 6
- However, PEP should be initiated regardless of time interval between exposure and presentation 1
- The incubation period typically ranges from 1-3 months but can extend from days to years 5
- Once clinical symptoms appear, rabies is nearly universally fatal—only 7 individuals have ever survived symptomatic rabies 7
Common Pitfalls to Avoid
- Waiting for laboratory confirmation before starting PEP—this is a fatal error 3
- Failing to infiltrate RIG into wounds—this occurs in 44% of cases despite being critical for local virus neutralization 4
- Administering vaccine in the gluteal area—this reduces immunogenicity 1
- Exceeding the recommended RIG dose—this suppresses active antibody production 1
- Inadequate wound cleansing—must be thorough (15 minutes) to mechanically remove virus 3
Geographic Considerations
- Availability of RIG varies significantly by region—Central and South America have the highest median delays (4.5 days) for RIG administration 6
- Travelers to high-risk areas should receive pre-exposure prophylaxis (3 doses on days 0,7, and 21 or 28) to simplify post-exposure management 5, 7
- Southeast Asia has the best RIG availability with no median delay 6
Evidence Strength
The 4-dose regimen recommendation is based on ACIP guidelines from 2010 that reviewed extensive peer-reviewed literature, unpublished data, and expert opinion 5, 1. This reduced schedule (from the previous 5-dose regimen) maintains 100% effectiveness when combined with proper wound care and RIG administration, while saving approximately $16.6 million annually in the U.S. healthcare system 1. The evidence demonstrates that virus-neutralizing antibodies peak by day 14-28, making the fifth dose on day 28 unnecessary for immunocompetent individuals 1.